я подготовила краткий обзор по наст

я подготовила краткий обзор по настоящей ситуации
как вы видите на данном слайде мы имеем большую задачу для включения 4 продуктов в формуляр и 8 продуктов в СКФ
Более того, мы планируем включить Бенефикс, и рассматриваем возможность для включения Ксалкори и Инлайта в орфанный список (где находятся Сутент и IRESSA (gefitinib))
Этот слайд показывает детальный план по включению в списки для Ксалкори и Инлайта, срок исполнения которого до третьего квартала этого года
Я хочу акцентировать на трудностях, с которыми мы сталкиваемся или столкнемся в будущем, которые не зависят от нас
1) Большая территория Казахстана, 16 регионов, прежде чем подписать письма-обоснования, нужно несколько раз встретиться со специалистами, после подписания писем главными внештатными специалистами, следующим этапом является подписание писем от региональных департаментов здравоохранения для внесения в Министерство здравоохранения
2) Заседания Формулярной комиссии не регулярные, нет утвержденного регламента.
Заседания могут проходить один раз в квартал или два раза в месяц

Results (English) 1:

I wrote a short review of the present situationas you can see on this slide, we have a great task to enable 4 products in form and 8 SKF productsMoreover, we plan to include Benefiks, and are considering the possibility to include Ksalkori and Inlajta in the orfannyj list (where are the Sutent and IRESSA (gefitinib))This slide shows a detailed plan for inclusion in the lists for Ksalkori and Inlajta, whose due date up to the third quarter of this yearI want to focus on the difficulties that we are facing or will face in the future that do not depend on us1) large area of Kazakhstan, 16 regions, before signing a letter of justification, need some time to meet experts, after the signing of letters of the main external experts, the next step is signing letters of regional departments of health for the Ministry of health2) meeting the Commission not regular Menu, there is no approved the rules.Meetings are held quarterly or twice a month

Results (English) 2:

I have prepared a brief overview of the present situation
as you can see on this slide, we have a big problem for the inclusion of products in Form 4 and 8 products in GFR
Moreover, we plan to incorporate Benefiks, and consider the possibility to include Ksalkori and Inlayta in Orff list (where the Sutent and IRESSA (gefitinib))
This slide shows a detailed plan for inclusion in the lists for Ksalkori and Inlayta, execution date until the third quarter of this year,
I want to focus on the challenges that we are facing or will face in the future, which does not depend on us
1 ) Most of the territory of Kazakhstan, 16 regions, before you sign a letter of justification, need some time to meet with experts, after the signing of letters main external experts, the next step is to sign the letters from the regional health departments to make the Ministry of Health
2) Formulary Committee meetings are not regular There are no regulatory approval.
Meetings may be held once a quarter or twice a month

Results (English) 3:

I have prepared a brief overview of the present situation
as you can see on this slide we have a great task to enable 4 products in a case and 8 products in SHBP
what's more, we plan to include Бенефикс,And considering the possibility for inclusion Ксалкори and Инлаита in орфанныи list (where are Сутент and IRESSA (gefitinib))
This slide shows a detailed plan for inclusion in the lists for Ксалкори and Инлаита,Period of execution which up to the third quarter this year
i i would like to emphasize the difficulties which we are facing or will face in the future, which are not dependent on the us
1) the greater the territory of Kazakhstan, 16 regions,Before you sign letters of justification, you have several times to meet with experts, after the signing of the letters the main freelance specialists,The next step is the signing letters from the regional departments of health to the Ministry of Health
2) Meetings Формулярнои commission is not regular, there is no approved rules.
The meetings could be held once a quarter or two times a month